A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

March 23 (Reuters) - Pfizer (PFE.N), opens new tab and Valneva (VLS.PA), opens new tab said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed ...

Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, insurance portfolio management, finance and accounting, personal investment and financial ...

GSK has secured an FDA expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus.

Pfizer has been hurt in recent years after the COVID-19 pandemic and recent drug pricing pressure. The stock now trades at a dividend yield of 6.5%. Despite continued pricing pressure, Pfizer stock ...

It has been a tough year for Plug Power (PLUG 6.88%) stock. At one point, shares were down in value by nearly 20%. But in recent sessions, shares have recovered strongly. In fact, Plug Power stock ...

Corin Cesaric-Epple is a Flex Editor at CNET. She received her bachelor's degree in journalism from the University of Missouri-Columbia. Before joining CNET, she covered crime at People Magazine and ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.